PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Drug therapy - Market size and forecast 2018-2023 • Vaccination - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • Congestive splenomegaly • Infiltrative splenomegaly • Neoplastic splenomegaly • Immune splenomegaly PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • GlaxoSmithKline plc • Incyte Corporation • Merck & Co., Inc. • Novartis AG • Sanofi PART 16: APPENDIX • Research methodology • List of abbreviations PART 17: EXPLORE TECHNAVIO   Exhibit 01: Global rare diseases therapeutics market Exhibit 02: Segments of global rare diseases therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline molecules for reduction in spleen size Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Drug therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: JAKAVI/JAKAFI sales in $ millions Exhibit 22: Drug therapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Vaccination - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Vaccination - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Asia - Year-over-year growth 2019-2023 (%) Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 36: ROW - Year-over-year growth 2019-2023 (%) Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Impact of drivers and challenges Exhibit 40: Vendor landscape Exhibit 41: Landscape disruption Exhibit 42: Vendors covered Exhibit 43: Vendor classification Exhibit 44: Market positioning of vendors Exhibit 45: GlaxoSmithKline plc - Vendor overview Exhibit 46: GlaxoSmithKline plc - Business segments Exhibit 47: GlaxoSmithKline plc - Organizational developments Exhibit 48: GlaxoSmithKline plc - Geographic focus Exhibit 49: GlaxoSmithKline plc - Segment focus Exhibit 50: GlaxoSmithKline plc - Key offerings Exhibit 51: Incyte Corporation - Vendor overview Exhibit 52: Incyte Corporation - Business segments Exhibit 53: Incyte Corporation - Organizational developments Exhibit 54: Incyte Corporation - Key offerings Exhibit 55: Merck & Co., Inc. - Vendor overview Exhibit 56: Merck & Co., Inc. - Business segments Exhibit 57: Merck & Co., Inc. - Organizational developments Exhibit 58: Merck & Co., Inc. - Geographic focus Exhibit 59: Merck & Co., Inc. - Segment focus Exhibit 60: Merck & Co., Inc. - Key offerings Exhibit 61: Novartis AG - Vendor overview Exhibit 62: Novartis AG - Business segments Exhibit 63: Novartis AG - Organizational developments Exhibit 64: Novartis AG - Geographic focus Exhibit 65: Novartis AG - Segment focus Exhibit 66: Novartis AG - Key offerings Exhibit 67: Sanofi - Vendor overview Exhibit 68: Sanofi - Business segments Exhibit 69: Sanofi - Organizational developments Exhibit 70: Sanofi - Geographic focus Exhibit 71: Sanofi - Segment focus Exhibit 72: Sanofi - Key offerings Exhibit 73: Validation techniques employed for market sizing

GlaxoSmithKline plc Incyte Corporation Merck & Co., Inc. Novartis AG Sanofi